Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Novavax, Inc. Stock Popped Today

By Cory Renauer - Updated Jul 18, 2017 at 12:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are cheering an upcoming update concerning its troubled lead vaccine candidate.

What happened

Shares of Novavax, Inc. (NVAX -2.68%), a clinical-stage biotech focused on novel vaccine development, jumped 24.6% higher as of 11:50 a.m. EDT on Tuesday. Investors are cheering in response to the company's announcement that it will hold a conference call next week to discuss recent progress with its RSV F vaccine.

So what 

The respiratory syncytial virus sends a staggering number of older adults and infants to hospitals each year, but a vaccine that effectively prevents infections has yet to emerge. Novavax came awfully close with a mid-stage study that just crossed the threshold for statistical significance, but the stock cratered last year when the RSV F vaccine couldn't repeat the success in a larger study.

Person looking up at a series of upward sloping arrows.

Image source: Getty Images.

An effective RSV vaccine could easily generate several billion in annual sales, and investors send this stock jumping at the slightest hint an application for approval of its candidate might eventually reach the Food and Drug Administration. Today's jump isn't in response to any actual data, at least not yet. Simply announcing a call to discuss top-line data from a mid-stage clinical trial is enough to ignite hope.

Now what

On July 24, 2017, management intends to present results from the phase 2 safety and immunogenicity trial with its RSV F vaccine in adults over 60 years of age. While the call will be worth a listen, it won't tell us a great deal about the candidate's chances of eventually earning an approval. Previous studies have already shown the vaccine is safe and that it stimulates immune systems to create RSV-fighting antibodies.

In a rational market, the only data that would inspire a stock movement like the one we've seen today would be results from the ongoing, late-stage maternal immunization study. Investors better settle in for a long wait. According to today's announcement, the pivotal trial, which involves dosing women while they're pregnant and then measuring RSV infection rates among their babies, is still enrolling patients.

Cory Renauer has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$60.27 (-2.68%) $-1.66

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.